AG真人官方

Enanta Pharmaceuticals to Present at the Jefferies Global Healthcare Conference

WATERTOWN, Mass.--(BUSINESS WIRE)-- (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases, today announced that Jay R. Luly, Ph.D., President and Chief Executive Officer, will participate in a fireside chat at the Jefferies Global Healthcare Conference on Thursday, June 5, 2025 at 8:10 a.m. ET in New York, NY.

A live webcast of the event will be accessible by visiting the 鈥淓vents and Presentations鈥� section on the 鈥淚nvestors鈥� page of Enanta鈥檚 website at . A replay of the webcast will be available following the presentation and will be archived for at least 30 days.

About Enanta Pharmaceuticals, Inc.
Enanta is using its robust, chemistry-driven approach and drug discovery capabilities to become a leader in the discovery and development of small molecule drugs with an emphasis on indications in virology and immunology. Enanta鈥檚 clinical programs are currently focused on respiratory syncytial virus (RSV) and its earlier-stage immunology pipeline aims to develop treatments for inflammatory diseases by targeting key drivers of the type 2 immune response, including KIT and STAT6 inhibition.

Glecaprevir, a protease inhibitor discovered by Enanta, is part of one of the leading treatment regimens for curing chronic hepatitis C virus (HCV) infection and is sold by AbbVie in numerous countries under the tradenames MAVYRET^庐 (U.S.) and MAVIRET^庐 (ex-U.S.) (glecaprevir/pibrentasvir). A portion of Enanta鈥檚 royalties from HCV products developed under its collaboration with AbbVie contribute ongoing funding to Enanta鈥檚 operations. Please visit for more information.

View source version on businesswire.com:

Media and Investors Contact:

Jennifer Viera

617-744-3848

[email protected]

Source: Enanta Pharmaceuticals, Inc.